Aldeyra Therapeutics (NASDAQ:ALDX) was upgraded by ValuEngine from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, ValuEngine reports.

ALDX has been the subject of a number of other research reports. Zacks Investment Research downgraded Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, August 14th. Cantor Fitzgerald set a $33.00 price objective on Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Tuesday, June 25th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $26.79.

Shares of ALDX stock traded up $0.68 on Tuesday, reaching $5.58. The company’s stock had a trading volume of 452,135 shares, compared to its average volume of 379,555. Aldeyra Therapeutics has a 12-month low of $4.31 and a 12-month high of $16.70. The company has a market capitalization of $135.96 million, a P/E ratio of -3.12 and a beta of 0.61. The stock’s 50 day simple moving average is $5.04 and its 200-day simple moving average is $6.82.

Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. On average, analysts predict that Aldeyra Therapeutics will post -2.01 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE grew its position in Aldeyra Therapeutics by 139.4% during the fourth quarter. Bank of America Corp DE now owns 12,181 shares of the biotechnology company’s stock valued at $102,000 after acquiring an additional 7,093 shares during the last quarter. Deutsche Bank AG raised its position in Aldeyra Therapeutics by 17.0% in the 4th quarter. Deutsche Bank AG now owns 39,658 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 5,753 shares during the period. BNP Paribas Arbitrage SA purchased a new position in Aldeyra Therapeutics in the 1st quarter worth $40,000. Rhumbline Advisers raised its position in Aldeyra Therapeutics by 17.3% in the 1st quarter. Rhumbline Advisers now owns 27,183 shares of the biotechnology company’s stock worth $245,000 after purchasing an additional 4,010 shares during the period. Finally, National Asset Management Inc. lifted its stake in Aldeyra Therapeutics by 69.4% in the first quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock worth $244,000 after purchasing an additional 11,066 shares during the last quarter. Hedge funds and other institutional investors own 61.26% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Read More: Coverage Ratio

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Aldeyra Therapeutics (NASDAQ:ALDX)

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.